| 000 | 00000cam 2200000zi 4500 |
| 001 | 9.966906 |
| 003 | CaOODSP |
| 005 | 20261113134352 |
| 006 | m o d f |
| 007 | cr cn||||||||| |
| 008 | 261019e202611 onca ob f000 0 eng d |
| 020 | |a9781100010342 |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 043 | |an-cn--- |
| 086 | 1 |aH164-327/2026E-1-PDF |
| 245 | 00|aGuidance on nitrosamine impurities in medications : |bevaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products. |
| 250 | |a[November 2026 edition]. |
| 264 | 1|a[Ottawa] : |bHealth Canada = Santé Canada, |cNovember 2026. |
| 264 | 4|c©2026 |
| 300 | |a1 online resource (iii, 64 pages) : |billustrations |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |aTitle from cover. |
| 500 | |aIssued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments : évaluation et gestion des risques posés par les impuretés de N-nitrosamine dans les produits pharmaceutiques, biologiques et radiopharmaceutiques destinés à l'usage humain. |
| 500 | |a"Health products." |
| 504 | |aIncludes bibliographical references (page 37). |
| 520 | |a"This guidance represents Health Canada's current thinking and recommendations on issues related to N-nitrosamine impurities (nitrosamine impurities or nitrosamines). This guidance may be subject to change as new information becomes available and if further guidance is needed for applicants and market authorization holders (MAHs)"--Background, page 1. |
| 650 | 0|aNitrosoamines|xRisk assessment|zCanada. |
| 650 | 0|aDrugs|xRisk assessment|zCanada. |
| 650 | 0|aBiologicals|xRisk assessment|zCanada. |
| 650 | 0|aRadiopharmaceuticals|xRisk assessment|zCanada. |
| 650 | 0|aPharmaceutical policy|zCanada. |
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
| 775 | 08|tLignes directrices sur les impuretés de nitrosamine dans les médicaments : |w(CaOODSP)9.966905 |
| 795 | |tGuidance on nitrosamine impurities in medications.|w(CaOODSP)9.962669 |
| 856 | 40|qPDF|s2.02 MB|uhttps://publications.gc.ca/collections/collection_2026/sc-hc/H164-327-2026-1-eng.pdf |
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html |